Table 2

Risk of T2DM according to plasma adiponectin

Continuous adiponectin
(per SD decrease in log2 transformed)P valueCategorized adiponectin (quartiles)Ptrend value
1234
Univariate1.69 (1.22–2.34)0.0014.14 (1.39–12.35)2.02 (0.61–6.70)1.99 (0.60–6.58)Reference0.008
Model 11.99 (1.34–2.94)0.0016.26 (1.51–25.80)2.77 (0.67–11.42)2.35 (0.66–8.32)Reference0.007
Model 21.97 (1.24–3.12)0.0045.86 (1.34–25.69)2.26 (0.50–10.14)2.29 (0.65–8.15)Reference0.017
Model 32.06 (1.23–3.46)0.0066.78 (1.11–41.28)2.41 (0.44–13.06)2.29 (0.57–9.14)Reference0.032
Model 41.91 (1.12–3.24)0.0177.18 (1.05–49.18)2.39 (0.45–12.54)1.95 (0.44–8.63)Reference0.040
  • Data are HR and 95% CI for risk of T2DM according to both continuous and categorized total plasma adiponectin calculated by Cox proportional hazards regression using competing risk analyses. Model 1, age and sex; model 2, model 1 + hypertension, hypercholesterolemia, current smoking, previous MI, BMI, and blood glucose; model 3, model 2 + total cholesterol, HDL, LDL, and triglyceride; model 4, model 3 + eGFR, CRP, peak TnI, and proANP.